United Devices continues expansion into European market with additional key customer

"Ease of deployment and the availability of applications were strong selling points for us", stated Sanofi-Synthelabo Head of Discovery IT, Olivier Gien. "We also needed proven scalability and security and knew from United Devices' other enterprise deployments and their work with their public Grid that massive scaling and security capabilities were already proven."

United Devices' Enterprise MetaProcessor platform allows customers to efficiently harness existing IT resources as a virtual supercomputer for high-throughput screening. When evaluating the appropriate technology solution, Sanofi-Synthelabo chose grid computing over a more expensive cluster solution in order to avoid heavy IT costs and depreciation of those dedicated assets while taking advantage of existing resources that will grow into a more powerful solution over time.

"The fact that France's top pharmaceutical company is using United Devices' grid software for virtual screening is a good indication that grid technology is becoming a standard enterprise platform for drug discovery", stated United Devices Chief Executive Officer, Ed Hubbard. "Undertaking a first-of-its kind Virtual Screening System, Sanofi-Synthelabo is also demonstrating their commitment toward progress."

The Enterprise MetaProcessor platform is an on-site grid computing platform that unobtrusively enables clusters, servers, desktops and workstations to act as a processing grid for data-intensive or computationally demanding research and analysis. The platform's architecture offers industry-leading features in security, transparency, reliability and manageability. Organisations can create grids of any scale to accelerate the performance of their business-critical processing in the most cost-effective manner.